Connect Biopharma says its new COPD treatment has 81% fewer failures than the old method.

CNTB · Connect Biopharma Holdings Limited

The AI's read

That gives CNTB early evidence that rademikibart may help some people with COPD and supports further testing. But the trial covered only 159 people and 8 weeks, so larger, longer studies still need to confirm the benefit.